logo
Twitter
Discord
Email
logo
China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc.

NASDAQ•SXTC
CEO: Mr. Feng Zhou
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2019-01-04
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
Contact Information
178 North Taidong Road, Taizhou, 225300, China
86-523-8629-8290
www.sxtchina.com
Market Cap
$10.96M
P/E (TTM)
-0.1
36.8
Dividend Yield
--
52W High
$6.98
52W Low
$0.08
52W Range
0%
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$455.71K-7.84%
4-Quarter Trend

EPS

-$0.51-119.10%
4-Quarter Trend

FCF

-$495.09K-26.95%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Regular TCMP Revenue Surge Regular TCMP revenue increased 53% to $1.44M for FY2025, offsetting a significant 73% drop in Advanced TCMP sales.
Cash Position Strengthened Cash and equivalents increased substantially to $18.13M by March 31, 2025, despite increased cash outflow from operations.
Gross Margin Compression Gross profit fell 34% to $367.4K; gross margin compressed to 21.1% due to lower margin Regular TCMP sales mix.
Advanced TCMP Sales Decline Advanced TCMP revenue plummeted 73% year-over-year to $258.4K, accounting for only 15% of total revenue in 2025.

Risk Factors

Internal Control Ineffective Disclosure controls deemed not effective as of March 31, 2025, citing material weaknesses in bilingual GAAP personnel and segregation.
High Customer Concentration Dependence on a small customer base; one customer generated 68.72% of total revenue during the fiscal year ended March 31, 2025.
PRC VIE Structure Risk Operations rely on VIE agreements, facing uncertainty regarding PRC law interpretation and potential unenforceability of contracts.
Net Loss Increased Net loss widened 7% to $3.30M for the year, primarily due to a 5% increase in general and administrative expenses.

Outlook

Promote Advanced TCMP Efficacy Plan to educate physicians on Advanced TCMP product safety and efficacy profiles to increase national brand recognition.
Expand Product Portfolio Focus development capabilities on expanding existing portfolio, including introducing new types of Advanced TCMP products steadily.
Increase Distribution Reach Intend to broaden marketing efforts outside major cities, targeting new markets in PRC cities and rural areas.
Maintain R&D Leadership Continue sharpening advantages in R&D, expecting to develop new Advanced TCMP products in the foreseeable future.

Peer Comparison

Revenue (TTM)

Journey Medical CorporationDERM
$59.40M
+2.8%
Tonix Pharmaceuticals Holding Corp.TNXP
$10.30M
-145.5%
Nkarta, Inc.NKTX
$9.03M
-14.3%

Gross Margin (Latest Quarter)

Incannex Healthcare Inc.IXHL
100.0%
+0.0pp
Fate Therapeutics, Inc.FATE
100.0%
+0.0pp
Journey Medical CorporationDERM
67.4%
+3.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ACHV$298.11M-3.7-196.7%19.1%
TNXP$234.28M-1.6-55.2%0.2%
DERM$200.07M-25.0-39.9%29.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.2%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 20-F - FY 2025

    Period End: Mar 31, 2025|Filed: Jul 31, 2025|
    Revenue: $1.74M-9.7%
    |
    EPS: $-8.18-129.1%
    N/A

  • Form 20-F - FY 2024

    Period End: Mar 31, 2024|Filed: Aug 13, 2024|
    Revenue: $1.93M-2.2%
    |
    EPS: $-3.57+83.9%
    Miss

  • Form 20-F - FY 2023

    Period End: Mar 31, 2023|Filed: Jul 31, 2023|
    Revenue: $1.97M-24.2%
    |
    EPS: $-22.23+83.9%
    N/A

  • Form 20-F/A - FY 2022

    Period End: Mar 31, 2022|Filed: May 19, 2023|
    Revenue: $2.60M-45.5%
    |
    EPS: $-137.92-44.4%
    N/A

  • Form 20-F - FY 2022

    Period End: Mar 31, 2022|Filed: Jul 18, 2022|Refer to amended data

  • Form 20-F - FY 2021

    Period End: Mar 31, 2021|Filed: Aug 13, 2021|
    Revenue: $4.78M-7.5%
    |
    EPS: $-95.48+88.5%
    N/A